Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 and ENaC in nephrotic syndrome
NL-OMON51030Withdrawn
- Sponsor
- Rijnstate
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of alirocumab, evolocumab and amiloride in nephrosis and hypercholesterolemia (2 cohorts), sponsored by Rijnstate. Primary endpoint: Serum LDL cholesterol. Planned start Mar 2021; status: withdrawn.
02
Drugs
alirocumabevolocumabamiloride
03
Conditions
nephrosishypercholesterolemia
Beyond the preview
Go deeper on NL-OMON51030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51030.